echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Longyu Pharmaceutical Cavosonstat in the treatment of moderate to severe asthma in China and the U.S. Phase II clinical trial launched

    Longyu Pharmaceutical Cavosonstat in the treatment of moderate to severe asthma in China and the U.S. Phase II clinical trial launched

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 11, Langyu Pharmaceutical Technology (Hangzhou) Co.
    , Ltd.
    (hereinafter referred to as "Langyu Pharmaceutical") announced the official launch of Phase II clinical trials of Cavosonstat (N91115), a new class I drug developed by it for the treatment of moderate to severe asthma
    .


    Among them, the United States has cooperated with the precise institution funded by the National Institutes of Health (NIH).


    Asthma has become one of the most common diseases in the world today
    .


    According to the Global Initiative for Asthma Prevention and Control (GINA), there are about 300 million people suffering from asthma in the world; according to WHO's forecast, the number of asthma patients will increase to 400 million by 2025


    Among the anti-inflammatory drugs currently on the market, inhaled corticosteroids are the mainstay and a small amount of interleukin inhibitors are injected


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.